RegulatoryPress Release: PannTheraPi Receives ANSM Approval to Advance PTI5803 into Phase 2a in Focal Cortical Dysplasiaseptembre 8, 2026
RegulatoryPress release: Panntherapi submitted the Phase2a trial for PTI5803 & appointed Sophie Binay as new General Manager and CSOavril 14, 2026
